KRAS inhibition in metastatic colorectal cancer: An update.

Abstract excerpt

About half of colorectal cancers harbor mutations in the KRAS gene. The presence of these mutations is associated with worse prognosis and, until now, the absence of matched targeted therapy options. In this review, we discuss clinical efforts to target KRAS in colorectal cancer from studies of downstream inhibitors to recent direct inhibitors of KRASG12C and other KRAS mutants. Early clinical trial data,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Mutation
• Share to Colorectal Neoplasms
• Share to Prognosis